Zonal Business Manager - South, Lung cancer
About the job
- A Bachelor of Pharmacy or Bachelor of Science degree is required.
- A minimum of 10 years of experience is required.
- Good understanding of Microsoft Excel, PowerPoint, and Microsoft tools.
- Proven analytical, communication, and presentation skills.
- Knowledge of business and procurement processes.
- Drive business growth with District Managers and Product Specialists in the assigned territory by delivering budgeted sales objectives while adhering to organizational policies.
- Build the team to maximize opportunities, optimize resources, and drive people development.
- Review team key performance indicators and ensure adherence to business requirements.
- Map territory potential against market trends and competitor activities to build sustainable business in the zone.
- Build and own long-term relationships with Key Opinion Leaders and key business leaders in the zone to strengthen business advocacy.
- Plan and execute scientific activities, including continuous medical education, in consultation with the medical affairs team.
- Execute marketing campaigns to serve listed healthcare practitioners in the prescribed territory.
- Focus on capability building and nurture talent to develop future leaders.
- Collaborate with internal and external partners for effective execution.
- Travel extensively to assigned ex-headquarters and out-station locations for around 50% of working days.
- A Master of Business Administration degree in addition to the required degree.
- Exposure to the targeted geographic area.
- Exposure to the oncology or specialty market.
- Clinical experience.
- Cross-functional collaboration.
- Customer centricity.
- Data savviness.
- Developing others and partnerships.
- Hematology knowledge.
- Inclusive leadership.
- Leadership.
- Market knowledge.
- Oncology knowledge.
- Performance measurement.
- Pharmaceutical industry and pharmaceutical sales marketing experience.
- Problem solving.
- Relationship building.
- Sales enablement.
- Sales trend analysis.
- Strategic sales planning.
- Strategic thinking.
- Team management.
About the company
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
- TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
- CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.
What critics are saying
- Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
- Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
- AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.
What makes Johnson & Johnson unique
- J&J has 28 billion-dollar products, reducing dependence on any single franchise.
- TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
- CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -1%Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.
Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.